MRI contrast developer Epix Pharmaceuticals reported sales of $1.1 million for the company's second quarter (end-June), compared to revenues of $3.2 million in the same period in 2004.
The Cambridge, MA, company's net loss grew during the quarter to $7.1 million, compared with a net loss of $5 million in the corresponding period of 2004.
Milestones achieved during the quarter included the Food and Drug Administration's acceptance of the company's response to questions in the agency's approvable letter for its Vasovist (MS-325) contrast agent, and a positive opinion from Europe's Committee for Medicinal Products for Human Use on marketing authorization for Vasovist.
By AuntMinnie.com staff writersJuly 28, 2005
Related Reading
Epix makes management moves, July 6, 2005
Epix's Vasovist moves closer to market, July 1, 2005
Epix submits response to FDA, May 23, 2005
Epix revenues, income down in Q1, April 29, 2005
Epix launches blood-clot agent trial, April 7, 2005
Copyright © 2005 AuntMinnie.com
